SequelSEC

Perspective Therapeutics, Inc. CATX

Pharmaceutical Preparations · CIK 0000728387 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
-$3.80M
Fiscal year ended 2023-12-31
Operating income
-$11.68M
Fiscal year ended 2023-12-31
Free cash flow
-$9.10M
Fiscal year ended 2023-12-31

Valuation, from the filing

Public float$212.87MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.87Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin100.0%97th
Current ratio1.07x17th

Perspective Therapeutics, Inc. (CATX) reported revenue of -$3.80M and net income of -$24.68M for the fiscal year ended 2023-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Perspective Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Perspective Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Revenue-$3.80M$2.18M$2.09M$2.06M-$7.13MUnavailable$2.50MUnavailable$2.82M$2.56M
Cost of revenueUnavailable$1.45M$1.84M$1.58MUnavailableUnavailable$1.58MUnavailable$1.60M$1.54M
Gross profit-$39.00K$738.00K$248.00K$487.00K-$2.78MUnavailable$926.00KUnavailable$1.22M$1.03M
Operating income-$11.68M-$9.75M-$9.75M-$9.76M-$982.00KUnavailable-$2.11MUnavailable-$1.64M-$2.27M
Net income-$24.68M-$10.36M-$11.11M-$371.00K-$3.27MUnavailable-$2.08MUnavailable-$1.60M-$2.24M
Research & development$7.08M$5.55M$5.37M$3.31M-$1.17MUnavailable$796.00KUnavailable$535.00K$702.00K
Weighted-average diluted sharesUnavailableshares 28.06Mshares 28.00Mshares 228.59MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$11.64M-$9.57M-$9.49M-$9.40M-$561.00KUnavailable-$2.08MUnavailableUnavailableUnavailable
Income tax expense$7.85M$0$0-$10.50M$0Unavailable$0UnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.37$-0.40$0.00UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$2.24MUnavailable$2.32M$2.60M
General & administrative$4.94M$4.47M$4.99M$6.66M$1.21MUnavailable$1.58MUnavailable$1.62M$1.84M
Selling & marketingUnavailable$855.00K$911.00K$812.00KUnavailableUnavailable$654.00KUnavailable$702.00K$761.00K

Balance

Perspective Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Cash & equivalents$9.24M$17.98M$28.32M$36.45M$20.99MUnavailable$55.89MUnavailable$60.35M$61.69M
Total assets$97.89M$110.52M$120.14M$127.64M$58.09MUnavailable$64.44MUnavailable$67.25M$68.71M
Current assets$16.84M$21.69M$31.95M$40.27M$53.22MUnavailable$59.33MUnavailable$63.60M$64.96M
Total liabilities$22.71M$11.75M$11.49M$9.62M$3.45MUnavailable$3.16MUnavailable$2.86M$2.95M
Current liabilities$15.66M$8.12M$8.59M$7.19M$3.12MUnavailable$2.27MUnavailable$1.84M$1.80M
Total equity incl. NCI$75.18M$98.77M$108.65M$118.03M$54.64MUnavailable$61.28MUnavailable$64.39M$65.76M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailable$1.01M$1.09M$1.41M$1.41MUnavailable$1.40MUnavailable$1.07M$1.06M
Accounts receivable$1.16M$1.73M$1.11M$1.36M$1.36MUnavailable$1.61MUnavailable$1.65M$1.90M
Goodwill$24.06M$27.32M$27.32M$27.32M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$1.72M$1.74M$1.77M$1.79MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Perspective Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Operating cash flow-$9.01M-$10.11M-$8.07M-$9.72M-$4.32MUnavailable-$2.89MUnavailable-$1.31M-$2.08M
Capital expenditures$89.00K$227.00K$555.00K$201.00K$61.00KUnavailable$105.00KUnavailable$81.00K$54.00K
Investing cash flow-$89.00K-$227.00K-$573.00K$25.26M$6.33MUnavailable-$123.00KUnavailable-$81.00K-$54.00K
Financing cash flow$352.00K$1.00K$512.00K-$80.00K$0Unavailable$0Unavailable$56.00K$0
Net change in cash-$8.74M-$10.34M-$8.13M$15.46M$2.00MUnavailable-$3.01MUnavailable-$1.34M-$2.14M
Stock-based compensation$720.00K$451.00K$1.20M$1.37M$207.00KUnavailable$154.00KUnavailable$180.00K$596.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$302.00K$259.00K$255.00K$190.00KUnavailableUnavailable$75.00KUnavailableUnavailableUnavailable

Derived

Perspective Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
Free cash flow-$9.10M-$10.34M-$8.63M-$9.92M-$4.38MUnavailable-$3.00MUnavailable-$1.39M-$2.14M
Gross marginUnavailable33.8%11.9%23.6%UnavailableUnavailable37.0%Unavailable43.3%40.1%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-84.1%UnavailableUnavailable-88.7%
FCF marginUnavailable-473.1%-413.2%-481.0%UnavailableUnavailable-119.6%Unavailable-49.5%-83.4%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable6.1%UnavailableUnavailable23.2%
Current ratio1.07x2.67x3.72x5.60x17.07xUnavailable26.18xUnavailable34.47x36.11x
Revenue YoY growthUnavailableUnavailable-16.6%Unavailable-353.3%Unavailable-7.6%Unavailable19.4%7.6%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-57.0%-87.5%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable31.8%UnavailableUnavailable27.4%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable4.2%UnavailableUnavailable2.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CATX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2022-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2022-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2022-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.